Instead of an exclusive deal, Zymeworks shared its platform non-exclusively with multiple pharma giants. This multi-partner strategy validated the technology, generated capital, and built a portfolio of royalty interests before the company developed its own internal pipeline.

Unlike traditional biotechs seeking pharma validation, Xaira's initial collaborations will be with tech companies for AI tools, lab automation, and compute. This reflects a strategy focused on building the core R&D engine first, seeking partners that accelerate platform development rather than provide capital.

In a tight funding environment, a significant portion of startups now secure pharma partnerships *before* their Series A. This pre-validation has become a major draw for VCs, signaling a shift where corporate buy-in is needed to de-risk early-stage science for investors.

Turbine's pharma partners consistently praised the deep biological competence of its science team. This ability to engage as scientific peers, not just data scientists, built essential trust for early deals when the AI platform was still largely unvalidated.

Biotech assets have both value ("cheese") and risks ("holes"). Kainova's CEO argues the key to successful deal-making is managing multiple parallel conversations. This lets you identify partners focused on the asset's potential and close when they are ready, rather than getting bogged down by those fixated on the risks.

Winning a 'Golden Ticket' from a major pharma company like Servier provides more than just lab space. It acts as a powerful external validation of the science, which in turn helps the startup gain credibility to win additional awards and attract investment from other major players like Eli Lilly and Ono Pharma.

Vivtex's $2.1B deal with Novo Nordisk wasn't from a single pitch; it was cultivated over many years, stemming from pre-existing academic relationships. The key was building mutual scientific trust by consistently sharing progress—and even failures—allowing Novo Nordisk to observe their journey long-term.

The landmark partnership with Novo Nordisk wasn't won through a sales pitch. It was the result of a multi-year scientific relationship built on transparency. Consistently presenting progress, including failures, at conferences established deep institutional trust and credibility that proved invaluable.

In an industry where technology often fails, Vivtex prioritizes successful execution over deal volume. The CEO stresses that being honest about capabilities and delivering on promises is more crucial for long-term reputation and future partnerships than simply getting an initial deal signed.